-
FDA Approval For Endologix's Nellix Likely Pushed To At Least 2020
Thursday, May 18, 2017 - 11:58am | 337Read More...Following the announcement by Endologix, Inc. (NASDAQ: ELGX) that it will no longer seek approval of the Nellix first generation device following a FDA meeting, Stifel said the potential U.S. approval is pushed to at least 2020 from the previous timeline of early-2018. The company would now...
-
Analyst On Endologix: No Sense In Downgrading Now
Thursday, May 18, 2017 - 10:45am | 593Read More...Endologix, Inc. (NASDAQ: ELGX) announced on Thursday after the market close that it needs to conduct a confirmatory clinical trial for its Nellix Endovascular Aneurysm Sealing System with the previously updated instructions for use and the Gen2 device design. This follows the company's meeting...
-
Canaccord Says The Nellix 'Carrot' Should Drive Endologix Higher
Monday, June 13, 2016 - 11:45am | 349Read More...Shares of Endologix, Inc. (NASDAQ: ELGX) rose more than 6 percent after Canaccord Genuity upgraded the stock to Buy from Neutral, saying that the Nellix "carrot" could be the key driver both this year and next. Nellix is an investigational EndoVascular Aneurysm Sealing (EVAS) system designed for...
-
Analysts At BTIG Confident In Endologix Following Meeting With Top Executives
Monday, August 25, 2014 - 3:42pm | 367Read More...Sean Lavin of BTIG upgraded shares of Endologix (NASDAQ: ELGX) to Buy. What's notable about the upgrade is that just a few weeks ago on July 7 shares were downgraded to Neutral from Buy. Lavin's decision to return to a Buy rating follows a visit to the company's head office. The analyst notes...
